Paradigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate

MT Newswires Live
May 15

Paradigm Biopharmaceuticals (ASX:PAR) said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium (iPPS) for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.

The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.

The first patient is expected to be enrolled in the third quarter of the year, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10